Gemin X Pharmaceuticals Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $225M

Gemin X Pharmaceuticals General Information

Description

Manufacturer of cancer therapeutics and drugs in the United States. The company provides GX15-070, a small molecule that reinitiates programmed cell death and apoptosis; GMX1777, which is a small molecule and inhibitor of NAD+ synthesis; and other oncology products, providing patients with cures and relief to various cancer inflections.

Contact Information

Website
www.geminx.com
Formerly Known As
Gemin X Biotechnologies
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 3575 Avenue du Parc
  • Suite 4310
  • Montreal, Quebec
  • Canada
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Corporate Office
  • 3575 Avenue du Parc
  • Suite 4310
  • Montreal, Quebec
  • Canada

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gemin X Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 01-Apr-2011 $225M Completed Clinical Trials - Phase 2
8. Later Stage VC (Series E) 04-Aug-2010 Completed Product Development
7. Later Stage VC (Series D) 20-Apr-2010 Completed Product Development
6. Later Stage VC (Series C) 01-Jul-2008 Completed Product Development
5. Later Stage VC 19-May-2005 Completed Product Development
4. Early Stage VC 01-Jan-2002 Completed Product Development
3. Early Stage VC 24-Aug-2001 Completed Product Development
2. Early Stage VC (Series B) 03-May-2001 $12.6M $15.6M Completed Product Development
1. Early Stage VC (Series A) 01-Jan-1998 $3M $3M Completed Product Development
To view Gemin X Pharmaceuticals’s complete valuation and funding history, request access »

Gemin X Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Manufacturer of cancer therapeutics and drugs in the United States. The company provides GX15-070, a small molecule that
Drug Discovery
Montreal, Canada

Santa Monica, CA
 

Wilmington, DE
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Gemin X Pharmaceuticals Competitors (24)

One of Gemin X Pharmaceuticals’s 24 competitors is Kite Pharma, a Formerly VC-backed company based in Santa Monica, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kite Pharma Formerly VC-backed Santa Monica, CA
Ayala Pharmaceuticals Corporation Wilmington, DE
Altimmune Formerly VC-backed Gaithersburg, MD
BioNTech Formerly VC-backed Mainz, Germany
Centrose Venture Capital-Backed Madison, WI
You’re viewing 5 of 24 competitors. Get the full list »

Gemin X Pharmaceuticals Former Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
BDC Capital Growth/Expansion Minority
CDP Innovation-Sofinov Venture Capital Minority
Fonds de solidarite FTQ PE/Buyout Minority
GrowthWorks Venture Capital Minority
H.I.G. HealthBridge Partners Growth/Expansion Minority
You’re viewing 5 of 19 investors. Get the full list »

Gemin X Pharmaceuticals FAQs

  • When was Gemin X Pharmaceuticals founded?

    Gemin X Pharmaceuticals was founded in 1998.

  • Where is Gemin X Pharmaceuticals headquartered?

    Gemin X Pharmaceuticals is headquartered in Montreal, Canada.

  • What industry is Gemin X Pharmaceuticals in?

    Gemin X Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Gemin X Pharmaceuticals a private or public company?

    Gemin X Pharmaceuticals is a Private company.

  • What is the current valuation of Gemin X Pharmaceuticals?

    The current valuation of Gemin X Pharmaceuticals is .

  • What is Gemin X Pharmaceuticals’s current revenue?

    The current revenue for Gemin X Pharmaceuticals is .

  • How much funding has Gemin X Pharmaceuticals raised over time?

    Gemin X Pharmaceuticals has raised $158M.

  • Who are Gemin X Pharmaceuticals’s investors?

    BDC Capital, CDP Innovation-Sofinov, Fonds de solidarite FTQ, GrowthWorks, and H.I.G. HealthBridge Partners are 5 of 19 investors who have invested in Gemin X Pharmaceuticals.

  • Who are Gemin X Pharmaceuticals’s competitors?

    Kite Pharma, Ayala Pharmaceuticals, Altimmune, BioNTech, and Centrose are some of the 24 competitors of Gemin X Pharmaceuticals.

  • When was Gemin X Pharmaceuticals acquired?

    Gemin X Pharmaceuticals was acquired on 01-Apr-2011.

  • Who acquired Gemin X Pharmaceuticals?

    Gemin X Pharmaceuticals was acquired by Cephalon.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process